SCHEMBL19957258

SCHEMBL19957258

Cn1cnc(-c2ccc3c(Cl)ccnc3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 1/20 0.44
CYP2A6 P11509 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2B6 P20813 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM2B Q8NHM5 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
FTO Q9C0B1 1/20 0.38
KDM5A P29375 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
TLR8 Q9NR97 1/20 0.37
MAPT P10636 1/20 0.37
RIPK2 O43353 3/20 0.37
RORC P51449 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
ALK Q9UM73 1/20 0.36
AXL P30530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4540057 0.76 CYP2E1 (0.49) CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL26086334 0.75 ALK (0.60) CCNCCDK8ALKLRRK2MET
SCHEMBL19957290 0.74 IDO1 (0.51) RIPK2LRRK2
SCHEMBL12786895 0.74 RET (0.52) MAPTRIPK2DYRK1BALKEGFR
SCHEMBL31121086 0.74 RET (0.52) MAPTRIPK2DYRK1BALKEGFR
SCHEMBL25404944 0.73 MAPKAPK2 (0.45) TLR8RIPK2ALKNR4A2SOS2
SCHEMBL22766280 0.73 RIPK1 (0.45) CCNCCDK8ALK
SCHEMBL20927392 0.73 LMNA (0.38) CCNCCDK8MAPTALKMET
SCHEMBL19957235 0.73 MET (0.37) CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL30996528 0.72 CYP2E1 (0.41) CYP2E1CYP2A6CYP2C9CYP2B6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 CYP2E1 2900/4885CYP2A6 2050/4885CYP2C9 964/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 CYP2E1 2900/4885CYP2A6 2050/4885CYP2C9 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.